Your browser doesn't support javascript.
loading
CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy.
Bankur, Mustafa Nissar; Keeling, Archie; Adil Shah, Khoodoruth Mohamed; Avenoso, Daniele.
Afiliación
  • Bankur MN; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
  • Keeling A; Neurosciences Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
  • Adil Shah KM; Radiology Department, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
  • Avenoso D; Department of Psychiatry, Hamad Medical Corporation, Doha 00000, Qatar.
Hematol Rep ; 14(3): 213-221, 2022 Jun 23.
Article en En | MEDLINE | ID: mdl-35893153
ABSTRACT
Herein, we present a case of cytomegalovirus (CMV) colitis that occurred after two cycles of azacitidine and venetoclax in a 64-year-old woman affected with acute myeloid leukaemia (AML) secondary to a previous diagnosis of a hypoplastic myelodysplastic syndrome (hypo-MDS). This patient never had detectable CMV viraemia, and there was no evidence of immune deficiency that could justify this opportunistic infection. Additionally, this is most likely the first report describing CMV colitis in a patient treated upfront with azacitidine and venetoclax.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Hematol Rep Año: 2022 Tipo del documento: Article